AZD-1480 - CAS# 935666-88-9 321 Treatment of primary inv(16) AML

Treatment of primary inv(16) AML patient blasts with AI-10-49 triggers selective cell death

Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2

Curr Med Res Opin

Smiles: CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N)C1CC(C1)CCC1NC2=CC=C(C=C2N=1)C(C)(C)C

A randomized

AZD-1480 - CAS# 935666-88-9 321 Treatment of primary inv(16) AMLAZD1480. CAS# 935666 88 9, is an orally bioavailable inhibitor of Janus associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK STAT (signal transducer and activator of transcription) signaling including activation of STAT3. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a